Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.6, while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PDBC | RXRX | |
|---|---|---|
52-Week High | $19.60 | $6.79 |
52-Week Low | $13.16 | $2.84 |
Market Cap | — | $1.86B |
Sector | — | Health |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.30, up 1.53% with a bullish technical signal from moving averages. Recent institutional buying from Concurrent Investment Advisors and Geneos Wealth Management signals confidence, though oscillators show bearish momentum with RSI levels indicating potential overbought conditions. The fund has delivered strong returns, outperforming the S&P 500 by nearly 10 percentage points since March 2024.
Commodity momentum faces headwinds despite geopolitical tensions, with a Seeking Alpha downgrade to hold citing weakening technicals. The fund offers defensive exposure amid market shifts away from tech, but investors face risks from potential commodity price volatility and Middle East conflict impacts on oil markets.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
